Pharmaron to acquire Biortus Biosciences, appoints new independent director

Pharmaron Beijing Co., Ltd. announced on October 28, 2025, an agreement to acquire an 82.54% equity interest in Biortus Biosciences Co., Ltd. for approximately RMB1,346 million. This acquisition aims to integrate Biortus's structural biology capabilities, including cryo-electron microscopy analysis, with Pharmaron's existing bioscience services.

In a related development, Mr. Tsang Kwan Hung Benson has resigned as an independent non-executive director, effective upon the approval of his successor at the upcoming extraordinary general meeting. The board has nominated Prof. Tsang King Fung as his replacement, with an annual remuneration of RMB300,000. Prof. Tsang's appointment will commence upon shareholder approval.

Additionally, Pharmaron plans to amend its Articles of Association, including dissolving the supervisory committee and delegating its functions to the audit committee, along with other updates to align with current regulations. These amendments will be subject to shareholder approval via a special resolution.